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Background: Hepatology research has focused on developing traditional therapies as pharmacological medicines
to treat liver cirrhosis. Thus, this study evaluated mechanisms of the hepatoprotective activity of Curcuma longa
rhizome ethanolic extract (CLRE) on thioacetamide-induced liver cirrhosis in rats.
Methods: The hepatoprotective effect of CLRE was measured in a rat model of thioacetamide-induced liver
cirrhosis over 8 weeks. Hepatic cytochrome P450 2E1 and serum levels of TGF-β1 and TNF-α were evaluated.
Oxidative stress was measured by malondialdehyde, urinary 8-hydroxyguanosine and nitrotyrosine levels. The
protective activity of CLRE free-radical scavenging mechanisms were evaluated through antioxidant enzymes.
Protein expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in animal blood sera was studied and
confirmed by immunohistochemistry of Bax, Bcl2 proteins and proliferating cell nuclear antigen.
Results: Histopathology, immunohistochemistry and liver biochemistry were significantly lower in the Curcuma
longa-treated groups compared with controls. CLRE induced apoptosis, inhibited hepatocytes proliferation but had
no effect on hepatic CYP2E1 levels.
Conclusion: The progression of liver cirrhosis could be inhibited by the antioxidant and anti-inflammatory activities
of CLRE and the normal status of the liver could be preserved.
Keywords: Curcuma longa, Antioxidant enzymes, Cytochrome P450 2E1 (CYP2E1), Histology, Oxidative stress,
ImmunohistochemistryBackground
Cirrhosis is the damage of liver cells and their gradual re-
placement with scar tissue that impairs blood flow
through the liver causing hepatocyte death and loss of
liver function [1]. Hepatic fibrosis occurs in response to
liver damage and regenerates apoptotic cells after repeated
injury [2]. This inflammatory response is accompanied by
limited deposition of extra cellular matrix (ECM), so that
if the regeneration of dying cells fails during persistent
liver injury, hepatocytes are replaced by abundant ECM,
including fibrillar collagen, depending on the origin of in-
jury [3]. Treatment options for common liver disease such* Correspondence: ammeen@um.edu.my
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reproduction in any medium, provided the oras cirrhosis, fatty liver and chronic hepatitis are problem-
atic. The effectiveness of treatments such as interferons,
colchicines, penicillamine and corticosteroids are incon-
sistent at best and the incidence of side-effects profound
[4]. Because of the role of oxidative stress in liver cirrhosis,
antioxidants have been proposed as a treatment for cirrho-
sis [5]. Several studies have demonstrated the protective
effects of antioxidants against induced liver injury by redu-
cing oxidative stress in cells [6,7]. A number of herbals
show promising activity, including Silymarin for liver
cirrhosis, glycyrrhizin for chronic viral hepatitis, and
herbal combinations from China and Japan that have been
proven for treatment of liver diseases [8]. Silymarin, a ref-
erence drug, is a flavonolignan from ″milk thistle″
Silybum marianum, and widely used for the treatment of
hepatitis and liver cirrhosis [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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belongs to the family Zingiberaceae, native to South Asia
and is commonly known as turmeric. In Malaysia, com-
monly known as Kunyit, turmeric plant is a popular in-
gredient for preparing culinary dishes. In addition, it is
used as herbal remedy due to the prevalent belief that
the plant has medical properties. In folk medicine, the
rhizome juice from C. longa is used in the treatment of
many diseases such as anthelmintic, asthma, gonorrhea
and urinary, and its essential oil is used in the treatment
of carminative, stomachic and tonic [10]. In traditional
medicine, several plants and herbs have been used
experimentally to treat liver disorders, including liver
cirrhosis, [11,12]. C. longa possesses antioxidant [13],
anti-tumor [14], antimicrobial [15], anti-inflammatory
[16], wound healing [17], and gastroprotective activities
[18]. The previous studies have also shown that the
aqueous extract of C. longa has hepatoprotective activity
against carbon tetrachloride toxicity [19]. In this study,
we assessed the hepatoprotective effect of the ethanolic
extract of C. longa rhizomes against TAA-induced liver
cirrhosis in Sprague Dawley rats.Methods
Preparation of CLRE
C. longa rhizomes were obtained from Ethno Company,
Kuala Lumpur, Malaysia and identified by comparison
with the voucher specimen (KLU41829) deposited at
the Herbarium of Rimba Ilmu, Institute of Biological
Sciences, University of Malaya, Kula Lumpur, Malaysia
The rhizomes were cleaned, dried, ground, weighed, and
homogenized in 95% ethanol at a ratio of 1:10 of plant
to ethanol and left to soak for 3 days at 25°C with occa-
sional shaking and stirring. The mixture was then fil-
tered and the resulting liquid was concentrated under
reduced pressure at 45°C in an EYELA rotary evaporator
to yield a dark gummy-yellow extract (7%, w/w). The
concentrated extract was then kept in the incubator at
45°C for 3 days to evaporate the ethanol residue yielding
the crude rhizome extract. Extracts were then dissolved
in 10% Tween-20 before being orally administrated to
animals in concentrations of 250 and 500 mg/kg body
weight (5ml/kg body weight).Total phenol content (TPC) of CLRE
The Total Phenol content (TPC) of the CLRE extract
was determined by the Folin Denis calorimetric method
using Folin-Ciocalteau reagent (Merck, Darmstadt,
Germany) in gallic acid equivalent in mg (GAE/mg
extract) [20]. CLRE (1 mg) was first dissolved in 1 mL
dimethyl sulfoxide (DMSO). Next, 20 μL of the extract
was added into 100 μL of Folin-Ciocalteau reagent, andthe resulting mixture was incubated in the dark for 3
min. Then, 100 μL of sodium carbonate (1 g/10 mL) so-
lution was added to the mixture, and mixed thoroughly.
The final mixture was kept in the dark for 1 h and its
absorbance (750 nm wavelength) was read by an ELISA
reader (UV 1601 spectrophotometer, Shimadzu, Japan).
All procedures were carried out in triplicate. Linear
standard curves were produced by serial dilution of
gallic acid (1 mg/mL DMSO) and the absorbance was
read at 750 nm.
Ferric reducing anti-oxidant power of CLRE
The ferric reducing anti-oxidant power (FRAP) of CLRE
was assayed according to the previously described
method [21] with slight modification. FRAP reagent was
prepared by adding 300 mM acetate buffer (3.1 mg so-
dium acetate/mL, pH 3.6) to 10 mM 2,4,6-tripyridyl-S-
triazine (TPTZ) solution (Merck, USA) and 20 mM
FeCl3.H2O (5.4 mg/mL). Ten μL of 1 mg/mL of CLRE
(equivalent to 500 mg/kg dose administrated daily to an-
imals) and the standards gallic acid, quercetin, ascorbic
acid, retin, trolox and 2,6-di-tert-butyl-4 methyl phenyl
(BHT) were each sampled with 10 μL of 0.1 mg/mL
Silymarin (equivalent to 50 mg/kg dose administrated
daily to animals) and added to 290 μL of TPTZ reagent
in triplicate wells. Absorbance was read at 593 nm using
an ELISA reader (Shimadzu, Japan) every 4 min for 2 h.
Experimental animals
Sixty-six healthy Sprague Dawley rats (180-250 g) were
used in the experiments. All rats were kept in wire-
bottomed cages at 25 ± 2°C, given tap water and stand-
ard pellet diet and exposed to a 12 h:12 h light–dark
cycle at 50–60% humidity in an animal room. Through-
out the experiments, all animals received human care
according to the criteria outlined in the “Guide for the
Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the na-
tional Institute of health. The study was approved by the
Ethics Committee for Animal Experimentation, Faculty
of Medicine, University of Malaya, Malaysia PM/28/08/
2009/MAA.Acute toxicity study
Eighteen males and eighteen females healthy rats were
assigned equally into 3 groups of 6 rats: vehicle (receiv-
ing 10% Tween-20 w/v, 5 mL/kg); or treated with 2 g/kg
or 5 g/kg of CLRE preparation, respectively. The animals
were fasted overnight but water prior to dosing. Food
was withheld for a further 3-4 h after dosing. The ani-
mals were observed for 30 min and at 2, 4, 8, 24 and 48
h after administration for the onset of clinical or toxico-
logical symptoms. The animals were sacrificed on the
Figure 1 Antioxidant activity of the CLRE compared with the
standards: gallic acid, quercetin, ascorbic acid, rutin, trolox,
BHT and the standard drug Silymarin. Values were expressed as
mean ± SEM.
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were determined using standard methods [22].
Induction of liver cirrhosis in rats
Thioacetamide (TAA, CH3-C(S)NH2) is a hepatotoxin
and hepatocarcinogenic when administered in the diet of
experimental animals, and is widely used as a model of
acute and chronic liver disease [23] Briefly, after admin-
istration of TAA in the diet, it is converted to TAA-S
-oxide (TASO) by hepatic microsomal cytochrome P450
2E1 (CYP2E1), then transformed to toxic thioacetamide
S-dioxide (TASO2) [24]. TASO2 damages biomolecules
of the liver leading to cirrhosis [25].
Male animals were randomly divided into 5 groups of 6
rats. Rats of Group 1 (normal control group) were orally
administrated with 10% Tween-20 (5 mL/kg) daily and
intraperitoneally (ip) injected with sterile distilled water
(1 mg/kg) thrice weekly. Groups 2–5 were administered
with TAA by intraperitoneal injection (200 mg/kg/mL)
three times a week to induce liver cirrhosis. Constant ex-
posure of this concentration of TAA induces pathological
changes in the liver comparable to the etiology of cirrhosis
in humans [26]. The stock solution was prepared (5 g/L)
by dissolving TAA crystals (Sigma-Aldrich, USA) in sterile
distilled water and stirred till completely dissolved [27].
Rats of Group 2 (cirrhosis control group) were orally
administrated with 10% Tween-20 (5 mL/kg) daily. Rats
of Group 3 (Silymarin-treated group) were orallyTable 1 Effect of CLRE on renal function tests in rats
Dose Sodium Potassium
(mM/L) (mM/L)
Vehicle (10% Tween-20) 139.79 ± 1.34 4.87 ± 0.47
Low dose CLRE (2 g/kg) 143.31 ± 2.11 5.14 ± 0.39
High dose CLRE (5 g/kg) 140.67 ± 2.67 5.09 ± 0.40
Values expressed as mean ± SEM. There are no significant differences between groadministrated with Silymarin (50 mg/kg) daily. Silymarin
(International Laboratory, USA) was properly dissolved in
10% Tween-20 and used as a standard drug. Rats of
Groups 4 and 5 (treatment groups) were orally adminis-
trated with CLRE at daily doses of 250 mg/kg and 500
mg/kg, respectively. The treatment procedure was consid-
ered an 8-week period due to the preventive nature of the
experiment (Silymarin and CLRE), protecting the liver
from further damage. At the end of the 8 weeks, the rats
were fasted for 24 h after the last treatment and perfused
under ketamine (30 mg/kg, 100 mg/mL) and xylazil
(3 mg/kg, 100 mg/mL) anesthesia [28]. Blood was with-
drawn through the jugular vein and collected for pro-
thrombin time ratio evaluation, biochemical examinations,
cytokines and apoptotic proteins assessment. Liver tissues
were excised, washed with ice cold normal saline, blotted
on filter paper and weighed. The tissues were examined
thoroughly for gross cirrhosis. They were prepared for
evaluation of the oxidative damages and histopathology
assessment. Liver tissues were homogenized (10% w/v) in
50 mM cold potassium phosphate buffer (pH 7.4) using a
Teflon homogenizer (Polytron, Heidolph RZR 1, Germany).
Then the tissue homogenates were centrifuged at 3500 rpm
for 15 min at 4°C in a centrifuge (Heraeus, Germany). The
supernatant of each sample was collected and frozen in ali-
quots for later use.
Biochemical analysis
Blood samples from animals were collected in sodium
citrate tubes for determining prothrombin time or in gel-
activated tubes for the assessment of specific liver markers.
The gel-activated tubes were allowed to clot, then
centrifuged at 3400 rpm for 10 min at 4°C. The serum
samples were collected for measuring liver markers,
alkaline phosphatase (AP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), total protein, albumen
and bilirubin. The markers were assayed with a spectro-
photometer at Central Diagnostic Laboratory of the Med-
ical Center of University Malaya.Assessment of hepatic CYP2E1 levels
The level of CYP2E1 in the liver tissue homogenate of all
rats was evaluated by following the instructions of a sand-
wich enzyme immunoassay (Uscn Life Science, China).Chloride Urea Creatinine
(mM/L) (mM/L) (µM/L)
104.81 ± 1.42 4.69 ± 0.42 40.10 ± 2.63
103.46 ± 2.04 4.97 ± 0.58 39.00 ± 2.71
103.70 ± 1.52 5.27 ± 0.52 38.82 ± 3.14
ups, significant value at P<0.05. CLRE: C. longa rhizomes ethanolic extract.
Table 2 Effect of CLRE on liver function tests in rats
Dose Total protein Albumin TB AP ALT AST GGT
(g/L) (g/L) (µM/L) (IU/L) (IU/L) (IU/L) (IU/L)
Vehicle (10% Tween 20) 68.33 ± 1.71 11.78 ± 0.76 1.74 ± 0.13 72.75 ± 5.53 37.65 ± 2.66 53.58 ± 5.20 4.50 ± 0.19
Low dose CLRE (2 g/kg) 71.17 ± 1.28 12.76 ± 0.58 2.15 ± 0.16 66.90 ± 5.40 39.17 ± 3.16 62.48 ± 2.63 4.08 ± 0..45
High dose CLRE (5 g/kg) 69.17 ± 1.85 12.26 ± 0.64 1.85 ± 0.46 70.08 ± 11.12 34.50 ± 2.91 55.17 ± 4.83 4.67 ± 0.33
Values expressed as mean ± SEM. There are no significant differences between groups. Significant value at P<0.05, TB: Total bilirubin; AP: Alkaline phosphatase;
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: G-Glutamyl transferase; CLRE: C. longa rhizomes ethanolic extract.
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coated capture antibody specific to CYP2E1 in a 96-well
plate for 2 h at 37°C. After mild rinsing, the sample was in-
cubated for 1 h at 37°C with 100 μL of biotin-conjugated
secondary antibody followed by three times washing byA
C
E
Figure 2 Representative histological sections of liver and kidney in ac
(10% Tween-20). (2C and 2D) Rats treated with 2 g/kg (5 ml/kg) CLRE. (2E
significant difference in the structures of liver and kidney between treated350 μL washing buffer. Streptavidin-Horse radish peroxid-
ase (HRP) was added (100 μl) to the sample and incubated
for 30 min at 37°C followed by 5 repeated washes.
Tetramethylbenzidine (TMB) was added (90 μL) to the
sample as a colorimetric reagent and incubated for 20 min,B
D
F
ute toxicity testing. (2A and 2B) Rats treated with 5 ml/kg vehicle
and 2F) Rats treated with 5 g/kg (5 ml/kg) CLRE. There was no
and control groups (H&E stain ×20).
Table 3 Effect of CLRE on liver index measurements from rats at the end of 8 weeks study
Treatment Body weight (g) Liver weight (g) Liver weight × 100/body weight
Normal rats 341.33 ± 6.18 8.43 ± 0.34 2.47 ± 0.06
Cirrhosis rats 216.83 ± 10.96 10.13 ± 0.54 4.70 ± 0.22**
Silymarin-treated rats 336 ± 9.187 9.12 ± 0.34 2.72 ± 0.14*
Low dose CLRE-treated rats (250 mg/kg) 249.17 ± 14.89 8.80 ± 0.29 3.58 ± 0.19*
High dose CLRE-treated rats (500 mg/kg) 351 ± 19.73 9.48 ± 0.19 2.74 ± 0.15*
Data are expressed as mean ± SEM. *P<0.001 compared with the cirrhosis control Group 2. **P<0.001 compared with normal control Group 1. CLRE: C. longa
rhizomes ethanolic extract.
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450 nm.
Evaluation of oxidative stress markers
Urine 8-OH-dG
8-hydroxy-2-deoxyguanosine (8-OH-dG) is a product of
DNA oxidative damage through reactive oxygen species
(ROS) and serves as an established oxidative stress
marker [29]. To evaluate the DNA oxidative damage,
urine samples from all animals were collected 24 h be-
fore sacrifice and stored (-80°C). The levels of 8-OH-dG
were measure according to the instructions of the
manufacturer (Genox KOG-HS10E, USA). In brief, in a
96-well microtiter plate, pre-coated with monoclonal
antibody specific for 8-OH-dG, a urine sample (50 μL)
was incubated at 4°C overnight. The plate was then
washed (5 times) with concentrated buffered saline
(pH=7.4). 100 μL of biotinylated secondary antibody was
added to the sample and incubated for 1 h at room
temperature followed by a 3-time rinsing. The chromatic
solution tetramethylbenzidine (TMB) was added (100
μL) and incubated at room temperature for 15 min in
dark. The reaction terminating solution (1M phosphoric
acid) was added (100 μL) and the plate was read with a
spectrophotometer at 450 nm.Hepatic nitrotyrosine
Nitrotyrosine, a marker for protein oxidation [30] was
assessed in liver tissue homogenate of all animals by ELISA
according to the manufacturer protocol (MyBiosource,
USA). Succinctly, 100 μL of the sample was incubated with
monoclonal Nitrotyrosine-HRP conjugate in a microtiter
plate. After 1 h of incubation, the plate was washed 5 times
by 350 μL wash solution. Then substrate specific to HRP
enzyme was added (100 μL) to the sample followed by 50
μL stop solution and the intensity of the produced colour
was measured with a spectrophotometer at 450 nm.
Hepatic malondialdehyde
Malondialdehyde (MDA) levels were measured in the
liver tissue homogenate of all experimental groups as a
measure for lipid peroxidation using thiobarbituric acidaccording to the manufacturer’s instructions (Cayman,
Sigma). Ready to use SDS solution was added (100 μL)
to the samples/standard (100 μL). Then 4 mL of the
colour reagent were added to the mixture. Samples and
standard solutions vials were immersed in boiling water
for 1 h. The reaction was stopped when they were incu-
bation in an ice bath for 10 min. All vials were then
centrifuged at 1600 × g for 10 min at 4°C. A set of dupli-
cated samples or standards were loaded into 96-well
plate, and their absorbance were read at 532 nm by a
spectrophotometer.Antioxidant enzyme assessment
Superoxide dismutase (SOD) and catalase (CAT) en-
zymes were measured for each liver tissue homogenate
(Cayman, USA). SOD activity was evaluated by tetrazo-
lium salt detecting superoxide radicals produced by the
action of xanthine oxidase on hypxanthine. Bovine
erythrocyte SOD was used to represent SOD standard
curve. 200 μL of tetrazolium salt solution was added to
10 μL standards or samples followed by fast addition of
20 μL of xanthine oxidase to initiate the reaction. The
plate was covered and incubated for 20 min on a plate
shaker (Barnstead Dubuque, USA) and the reading of
the spectrophotometer was recorded at 450 nm. CAT ac-
tivity was evaluated by the chromagen, 4-amino-3
hydrazino-5-mercapto-1,2,4-triazole which measures the
formaldehyde produced by the reaction of CAT enzyme
with methanol in the presence of H2O2. The standard
curve was obtained by catalase formaldehyde standard.
Assay buffer (100 μL) and methanol (30 μL) were added
to the standards or samples (20 μL) and the reaction
was initiated when 20 μL of H2O2 was added. The plate
was incubated in dark at room temperature for 20 min.
Then Potassium Phosphate buffer (30 μL) was added to
terminate the reaction. Chromagen was added (30 μL)
and the plate was incubated on a shaker at room
temperature in the dark. After 10 min, catalase potas-
sium periodate was added (10 μL) and the plate was cov-
ered and left on the shaker at room temperature for 5
min. The absorbance was measure with a spectropho-












































































































Figure 3 Effect of CLRE on the plasma level of specific liver enzymes from rats at the end of 8 weeks study. AP: alkaline phosphatase;
ALT: alanine transferase; AST: aspartate transferase. Data were expressed as mean ± SEM. *P<0.001 compared with the normal control Group 1.
**P<0.001 compared with cirrhosis control Group 2. ***P<0.05 compared with cirrhosis control Group 2.
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Blood samples from each group was centrifuged at
3500 rpm and the sera were stored (-80°C) in aliquots for
assessment of transforming growth factor-beta (TGF-β), a
fibrogenesis-driving cytokine, and tumornecrosisfactor-
alpha (TNF-α), according to the manufacturers’ instruc-
tions (Abnova, USA). Briefly, the captured antibody was
diluted with the sample buffer provided and added onto
96-plate pre-coated with anti-rat antibody specific to
TGF-β or TNF-α. After the recommended incubation
period, biotinylated anti-rat specific antibody was added
and left incubated at 37°C in the dark. Then the samples
and the standards were incubated with streptavidin-HRP
conjugate which was washed with the washing buffer. The
wells were then incubated with the colorimetric reagent
TMB and the reaction was stopped so that to read the ab-
sorbance at 450 nm. The concentrations were calculated
by the optical density measurements from the obtained
standard curve.
Pro-apoptotic Bax and anti-apoptotic Bcl-2 assessment
Rat Bax ELISA kit and Rat Bcl-2 ELISA kit (Uscn Life
Science, China) were used to evaluate the expression of


















































Figure 4 Effect of CLRE on the total protein, albumen and bilirubin o
SEM. *P<0.001 compared with normal control Group 1. **P<0.001 compare
control Group1. *#P<0.01 compared with cirrhosis control Group 2.samples stored at -80°C were warmed up in 37°C bath
and then protein concentration in the samples was mea-
sured. The absorbance was read at 450 nm and the con-
centration ratio of Bax/ Bcl-2 was then calculated
accordingly.
Histopathological analysis
Liver samples were fixed in 10% buffered formaldehyde,
processed by an automated tissue processing machine
followed by paraffin wax embedding. Sections (5 μm in
thickness) were prepared and stained with hematoxylin
and eosin (H&E) for histopathological examination of
the liver tissue. Staining with Masson’s Trichrome
(Sigma, USA) was used as a marker of fibrosis to assess
the degree of fibrosis by identifying collagen fibers in
liver tissues. All the slides were examined under a light
microscope and images were captured with a Nikon
microscope (Y-THS, Japan).
Immunohistochemistry
Liver tissue sections were heated at 60°C for 25 min in
an oven (Venticell, MMM, Einrichtungen. Germany)
and then deparaffinized in xylene and rehydrated using





















































f rats at the end of 8 weeks study. Data were expressed as mean ±








































































































Figure 5 Effect of CLRE on the prothrombin time ratio of rats
at the end of 8 weeks study. Data were expressed as mean ±
SEM. *P<0.001 compared with the normal control Group 1.
**P<0.001 compared with cirrhosis Group 2. ***P<0.01 compared
with cirrhosis control Group 2.
Salama et al. BMC Complementary and Alternative Medicine 2013, 13:56 Page 7 of 17
http://www.biomedcentral.com/1472-6882/13/56performed in 10 mM sodium citrate buffer boiled in a
microwave. Immunohistochemistry staining steps were
performed following the manufacturer’s instructions
(DakoCytomation, USA). In brief, endogenous peroxid-
ase was blocked using 0.03% hydrogen peroxide sodium
azide for 5 min. Tissue sections were washed gently with
wash buffer and then incubated with Bcl-2–associated X
protein (Bax) (1:500), Proliferating Cell Nuclear Antigen
(PCNA) (1:200) and anti-apoptotic protein Bcl2 (1:50)
biotinylated primary antibodies for 15 min. Sections
were gently washed with wash buffer and kept in the
buffer bath in a humid chamber. A sufficient amount of
streptavidin-HRP was then added and incubated for 15
min followed by washing. Diaminobenzidine-substrate
chromagen was added to the sections and incubated for
over 7 min followed by washing and counterstaining

































































































Figure 6 Effect of CLRE on hepatic levels of CYP2E1 in rats at
the end of 8 weeks study. Data were expressed as mean ± SEM.
*P<0.01 compared with the normal control Group 1. **P<0.05
compared with cirrhosis control Group 2. No significant difference
was observed between the low dose CLRE-treated Group 4 and
high dose CLRE-treated Group 5 when compared with cirrhosis
Group 2.dipped in weak ammonia (0.037 M/L) 10 times, washed
and cover slipped. Positive antigens stained brown under
light microscopy.
Statistical analysis
Statistical analysis of the results was performed using one-
way ANOVA (Tukey Post-Hoc Test analysis) using SPSS
version 18 (SPSS Inc, USA). All values were reported as
mean ± SEM and a value of P<0.05 was considered
statistically.Results
TPC and FRAP results
The TPC of the CLRE was 517.54 ± 0.049 mg GAE/mg
extract, while the calibration curve equation was y =
0.15× + 0.0557, R2 = 0.9867. The FRAP of 1 mg/mL of
CLRE measured 1736.7 ± 0.032 nM/1 mg (Figure 1),
which is relatively lower than the standards for gallic
acid, quercetin, ascorbic acid, rutin, trolox and BHT.
However, the measured value of CLRE was comparable
to the reference drug Silymarin which is 600.56 ± 0.003
nM/ 0.1 mg (Figure 1). This suggested that CLRE
contained sufficient anti-oxidant efficacy to maintain the
liver status quo.
CLRE does not induce acute toxicity
Following CLRE administration, all animals remained alive
and did not manifest any visible toxicity at the doses used.
Clinical observations and serum biochemistry did not
show any significant differences between the control and
the treated groups (Tables 1 and 2). Histopathology results
of both liver and kidney (Figure 2) did not show any
significant differences between controls and the treated
groups.Effect of CLRE on liver cirrhosis
Body weight
Before sacrifice, the total body weight of each rat was
measured. Rats from the normal control group (Group
1) followed a normal pattern of growth and attained a
normal weight gain reaching 341.33 ± 6.184 g over 8
weeks. The cirrhosis rats (Group 2) suffered growth re-
tardation and had a significantly (P<0.05) lower weight
than other groups. When the body weights were fac-
tored in, rats from Group 2 measured the highest liver
index. Silymarin-treated rats (Group 3) and the rats
treated with a high dose (500 mg/kg) of CLRE extract
(Group 5) attained weights equivalent to Group 1, the
normal rats. Rats treated with the low dose (250 mg/kg)
of CLRE extract (Group 4) gained more weight than
those of Group 2 but not as much as those attained in
Group 3 and 5 (Table 3). These findings suggested that
Table 4 Effect of CLRE on OHdG, Nitrotyrosine and MDA from rats at the end of 8 weeks study
Treatment 8-OH-dG (ng/mL) Nitrotyrosine (ng/mL) MDA (nM/mg protein)
Normal rats 2.17 ± 0.33 1.06 ± 0.07 2.17 ± 0.33
Cirrhosis rats 5.40 ± 0.34** 3.87 ± 0.13** 5.40 ± 0.34**
Silymarin-treated Rats 2.80 ± 0.15* 1.67 ± 0.07* 2.80 ± 0.15*
Low Dose CLRE-treated rats (250 mg/kg) 2.83 ± 0.33* 1.40 ± 0.20* 2.83 ± 0.33*
High Dose CLRE-treated rats (500 mg/kg) 2.37 ± 0.88* 1.33 ± 0.13* 2.37 ± 0.88*
Data are expressed as mean ± SEM. *P<0.001 compared with the cirrhosis control Group 2. **P<0.001 compared with normal control Group 1. CLRE: C. longa
rhizomes ethanolic extract.
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ive as Silymarin in attenuating cirrhosis progression.Specific liver markers and total protein, albumen and
Bilirubin
The plasma levels of specific liver enzymes and protein
profile was measured to determine the liver function of
each rat (Figures 3, 4 and 5). The liver damage induced
by TAA toxicity significantly (P<0.001) elevated the
plasma level of specific liver enzymes (AP, ALT, AST,
bilirubin and prothrombin time ratio) and significantly
(P<0.001) lowered protein and albumen levels in the
hepatotoxic rats of Group 2 compared with the other
groups. The high dose CLRE-treated rats (Group 5)
resulted in comparable biochemical marker readings to
those of normal control Group 1 and Silymarin-treated
Group 3, and better than those recorded from the
low dose CLRE-treated rats (Group 4). These data dem-
onstrated that the effects of toxicity induced by TAA on
the liver function could be effectively counterbalanced
by CLRE treatment.Hepatic CYP2E1 levels
As shown in Figure 6, animals from the cirrhosis Group
2 had significantly (P<0.001) higher levels of CYP2E1
compared with the normal Group 1 and Silymarin-
treated Group 3. However, there was no difference be-
tween the low dose CLRE-treated animals of Group 4
and high dose CLRE-treated animals of Group 5 which
had similar CYP2E1 levels, or between these groups and
the cirrhosis Group 2.Oxidative stress markers
Oxidative stress parameters (liver tissue homogenate
MDA, nitrotyrosine, and urinary 8-OH-dG) are shown in
Table 4. Generally, the cirrhosis rats treated with TAA
only, had significantly higher levels of oxidative stress
biomarkers (P<0.001) than the normal rats and the experi-
mental treatment groups. Notably, the experimental rats
treated with low dose and high dose CLRE hadsignificantly lower levels (P< 0.001) of liver MDA and
nitrotyrosine compared with the cirrhosis rats of Group 2.
In addition, low and high dose treated rats had signifi-
cantly lower levels (P<0.001) of urinary 8-OH-dG contents
in comparison to the cirrhosis rats. Moreover, there were
no significant differences in the tested oxidative stress bio-
markers between CLRE-treated animals and Silymarin-
treated animals. These results suggest that treatment with
CLRE may protect hepatic cells from further damage dur-
ing cirrhosis.
Hepatocellular antioxidant enzymes
The loss of hepatocytes in the cirrhotic livers of animals
was indirectly analyzed by the activity of the antioxidant
enzymes (SOD and CAT). SOD and CAT results were
similar to that of the oxidative stress biomarkers
(Figures 7 and 8), but inversely, so the values of SOD
and CAT in the cirrhotic rats were lower than in the
normal rats. These results indicated the occurrence of
severe damage in the cells of cirrhotic livers. Treating
the cirrhotic animals with low and high dose CLRE sig-
nificantly (P<0.05) increased the levels of SOD and CAT
and induced the survival of hepatocytes. These results
collectively supported the suggestion that treatment with
CLRE could provide a favorable host environment for
protecting the hepatocytes from progressive damage.
Cytokine assessment
The serum levels of the cytokines TGF-β and TNF-α from
samples collected from all sacrificed rats are shown in
Figure 9. TGF-β1 and TNF-α levels were significantly ele-
vated (P<0.001) in serum samples from the cirrhosis Group
2 (100.11 ± 10.67 and 343.41 ± 4.66 pg/mL, respectively)
compared with all other groups. Administration of CLRE to
animals reduced the serum levels of the fibrogenic factor
TGF-β1 in the low dose CLRE-treated rats (61.72 ± 6.27
pg/mL) and in the high dose CLRE-treated rats (34.11 ±
0.84 pg/mL). In addition, the serum levels of the inflamma-
tory mediator TNF-α decreased in the low dose CLRE-
treated group 4 (272.73 ± 1.61 pg/mL) and in the high dose
CLRE-treated Group 5 (226.30 ± 2.01 pg/mL). Levels of
TGF-β1 and TNF-α from the high dose CLRE-treated rats
approached the values from the Silymarin-treated group
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pared with higher values in the low dose CLRE-treated rats.
Pro-apoptotic Bax and anti-apoptotic Bcl-2 assessment
The level of the pro-apoptotic protein Bax and the anti-
apoptotic protein Bcl-2 in the rat sea and the ratio of Bax/
Bcl-2 are shown in Figures 10 and 11. Results of Bax
showed no significance differences between the cirrhosis
group 2 and the normal group 1. On the other hand, there
was significant increase (P<0.001) in the level of Bax in
silymarin-treated Group 3, low dose CLRE-treated Group
4 and high dose CLRE-treated group 5 (4.98 ± 0.11, 4.47 ±
0.15 and 5.43 ± 0.12 ng/mL respectively) compared to the
cirrhosis group 2. The level of anti-apoptotic protein Bcl-2
showed significant increase (P<0.05) in the cirrhosis group
2 compared with the normal group 1 (2.57 ± 0.23 and
0.89 ± 0.09 ng/mL respectively), whereas no significance
differences were observed between the high dose and the
low dose treated groups when compared with the cirrhosis
group 2 indicating enhanced apoptosis in silymarin and
CLRE- treated groups as confirmed by the ratio Bax/Bcl-2
in Figure 11.
Gross anatomy and histopathology
The gross appearances of the liver samples and micro-
scopic assessment (H&E staining) of their sections in the
experimental Groups 1–5 are shown in Figures 12 and 13.
The gross appearance of livers from the normal rats in
Group 1 (Figure 12A) appeared reddish with smooth sur-
faces and without signs of nodules, and histology showed
normal architecture (Figure 13A). Livers from the cir-
rhotic rats of Group 2 appeared congested with numerous
micro- and macro-nodules (Figure 12B). The normal liver
architecture was lost and replaced by regenerating nodules
that were separated by fibrous septae extending from the
central vein to the portal triad (Figure 13B) and accom-




































































































Figure 7 Effect of CLRE on the levels of SOD enzyme in liver
tissue homogenate at the end of 8 weeks study. Data were
expressed as mean ± SEM. *P<0.05 compared with the normal
control Group 1. **P<0.05 compared with cirrhosis control Group 2.with invasive inflammatory cells. In addition, thick purple
bundles of collagen fibers appeared in the cirrhotic nod-
ules. The livers of Silymarin-treated Group 3 (Figures 12C
and 13C) and the high dose CLRE-treated Group 5
(Figures 12E and 13E) showed minor- micro-nodules with
less fibrous septae and more extension of normal hepatic
parenchyma. In contrast, the livers of the low dose CLRE-
treated Group 4 (Figures 12D and 13D) showed less fi-
brotic macro-nodules than those of the Silymarin-treated
Group 3, but the improvements were not great as those
seen in Groups 3 and 5. These visual evaluations provide
further independent confirmation that CLRE treatment ef-
fectively protected the liver from further cirrhosis in a
dose dependent manner.
Masson’s Trichrome staining
The degree of fibrosis determined by Masson’s trichrome
staining of the liver sections from all of the treated groups
is illustrated in Figure 14. Liver sections from the normal
rats (Figure 14A) appeared normal without signs of colla-
gen deposition. Liver sections from the cirrhosis rats of
Group 2 revealed increased deposition of collagen fibers
around the congested central vein indicating severe fibrosis
(Figure 14B). Liver tissues from Silymarin-treated Group 3
(Figure 14C) showed minimal collagen deposition indicat-
ing minimal fibrosis. Livers from rats treated with low dose
CLRE showed moderate deposition of collagen fibers and
moderate congestion around the central vein (Figure 14D),
while those from rats treated with high dose CLRE showed
mild collagen deposition and mild congestion around the
central vein (Figure 12E). This evaluation of the degree of
fibrosis confirms the previous findings that CLRE treatment
protected the livers of animals from progressive fibrosis.
Immunohistochemistry of Bax, Bcl2 and PCNA
Bax, Bcl2 and PCNA staining of hepatocytes from the




































































































Figure 8 Effect of CLRE on the levels of CAT in liver tissue
homogenate at the end of 8 weeks study. Data were expressed
as mean ± SEM. *P<0.001 compared with the normal control Group




































































































Figure 9 Effect of CLRE on the serum levels of cytokines at the
end of 8 weeks study. Data were expressed as mean ± SEM.
*P<0.001compared with the cirrhosis control Group 2. **P<0.001




























































































Figure 11 The ratio between pro-apoptotic protein Bax and
anti-apoptotic protein Bcl-2. Data were expressed as mean ± SEM.
*P<0.01compared with normal control Group 1. **P<0.001 compared
with cirrhosis control Group.
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http://www.biomedcentral.com/1472-6882/13/5615B and 16. Hepatocytes of liver tissues from the cirrhosis
rats of Group 2 showed down-regulation of Bax staining
(Figure 15A-15I) with up-regulation of Bcl2-positive hepa-
tocytes (Figure 15B-15I) and more PCNA staining
(Figure 16B) indicating severe damage with increased
number of necrotic cells than their apoptosis. Hepatocytes
from Silymarin-treated rats of Group 3 showed up-
regulated Bax expression (Figure 15A-II), down-regulated
Bcl2 expression (Figure 15B-II) and, a few PCNA staining
(Figure 16C) indicating lower levels of proliferation of
necrotized hepatocytes and enhanced apoptosis. Liver tis-
sues treated with low dose CLRE and high dose CLRE in-
duced hepatocyte apoptosis as indicated by up-regulated
Bax expression (Figures 15A-III and 15A-V), down-
regulated Bcl2 (Figures 15B-III and 15B-V) and down-
regulated necrotized hepatocytes’ proliferation as indicated
by reduced PCNA staining (Figures 16D and 16E). These
















































Figure 10 Effect of CLRE on the serum levels of the pro-apoptotic Ba
expressed as mean ± SEM. *P<0.001compared with the cirrhosis control Grinduce hepatoprotective activity against progressive liver
damage by increasing apoptosis of damaged hepatocytes
and ameliorating their proliferation.
Discussion
Prescription drugs with side effects have become widely
used in modern life and as a result, liver cirrhosis has be-
come a serious health problem. Consequently, the current
study focused on finding new therapeutic solutions to
minimize liver damage [31]. Natural products, especially
plants in folk medicine with an anecdotal history of posi-
tive effects against liver diseases or other organs, are con-
sidered an alternative therapeutic approach [32]. In the
present research, the ethanol extract of C. longa rhizomes
was examined as a promising therapy for treating liver cir-
rhosis. This study evaluated the toxicity of CLRE along
with the clinical biochemistry values, which confirmed by
the biochemical results (Tables 1 and 2). In addition, histo-
logical examination showed no significant pathological ab-
















































x and anti-apoptotic Bcl-2 at the end of 8 weeks study. Data were




Figure 12 Representative images showing the macroscopic appearances of livers sampled from rats in different experimental groups.
(12A) The liver of a control rat exhibiting a regular smooth surface. (12B) The liver of a hepatotoxic rat depicting numerous irregular whitish
micro- and macronodules on its surface and a large area of ductular cholangiocellular proliferation (arrow) embedded within fibrotic areas. (12C)
The liver of a hepatoprotected rat treated with Silymarin showing a normal smooth surface. (12D) The liver of a rat treated with low dose CLRE
with a nearly smooth surface with few granules (arrow head). (12E) The liver of a rat treated with high dose CLRE with a normal smooth surface.
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CLRE on the development of liver cirrhosis, induced by
prolonged exposure to TAA (200 mg/kg ) were assessed
though this study. The protocol induced cirrhosis with
similar pathology and etiology pattern to the human liver
cirrhosis with the same biochemical values for typical hu-
man cirrhosis markers [33]. The results were reconfirmed
quantitatively by measurement of the liver index of the
cirrhotic animals (Table 3), the biochemical imbalances in
the liver markers (Figures 3 and 5) and the altered total
protein content, albumen and bilirubin levels (Figure 4). A
marked reduction of plasma total protein levels were
observed in the cirrhosis control Group 2 compared with
the normal healthy animals of Group 1 (Figure 4), asdescribed in other TAA intoxication models [34]. Hepatic
factors (AP, ALT, and AST) were significantly increased in
the cirrhosis control rats, as previously described [34].
CLRE-treatment caused significant recovery of these en-
zymatic activities (Figure 3). Parallel findings were also
previously reported [35].
TAA has been used to induce hepatotoxicity in the
experimental animals to produce various grades of
liver damage including nodular cirrhosis, liver cell prolifera-
tion, production of pseudolobules, and parenchymal cell
necrosis [36]. It is a potent hepatotoxic agent metabolized
by CYP2E1 enzymes present in liver microsomes and
is converted to a toxic reactive intermediate called




Figure 13 Examples of representative histopathological sections from livers sampled from rats in different experimental groups. (13A)
Normal histological structure and architecture were seen in livers from the control rats. (13B) Severe structural damage, formation of pseudolobules
with thick fibrotic septa and necrotic areas were present in the livers of hepatotoxic rats. (13C) Mild inflammation but no fibrotic septae were observed
in the liver of the hepatoprotective rat treated with Silymarin. (13D) Partially preserved hepatocytes and architecture with small area of necrosis and
fibrotic septa were observed in the livers of rats treated with low dose CLRE. (13E) Partially preserved hepatocytes and architecture with small areas of
mild necrosis were observed in the liver of rats treated with high dose CLRE. (H&E stain, original magnification ×20).
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found that CLRE extract administration was not as effective
as Silymarin (Figure 6) in terms of hepatic CYP2E1 inhib-
ition and attenuating drug-induced hepatotoxicity [38]. Par-
allel findings reported that curcumin, the active ingredient
of C. longa rhizomes and constitutes 2.5-6% of the plant
rhizome constituents [39] had no significant effect on
CYP2E1 [30,40].
The development of liver cirrhosis by TAA was
reported to be multifaceted involving multiple mecha-
nisms [41]. For instance, TAA induces hepatocyte dam-
age via its metabolite, TASO2, which covalently binds to
macromolecules of hepatocytes causing DNA damage,
protein oxidation and lipid peroxidation of the cellmembrane biomolecules [25,42]. In the present study,
we evaluated the oxidative stress markers and observed
that the level of damage to liver cells due to oxidative
stress was very high in the cirrhosis rats of Group 2 as
indicated by high levels of urine 8-OH-dG, nitrotyrosine
and MDA (Table 4). However, the levels in low-dose and
high dose CLRE-treated rats were encouragingly close to
that of Silymarin-treated rats, supporting previous stud-
ies on the protective effect of C. longa against oxidative
stress by down-regulation of ROS [43] by inhibiting
DNA damage and attenuating protein and lipid oxida-
tion of hepatocytes as indicated by low levels of urine





Figure 14 Masson’s Trichrome staining of representative livers sampled from rats in different experimental groups. (14A) Normal liver
structure without signs of collagen deposition in livers from control rats. (14B) Severe collagen deposition (arrow) and severe fibrosis were seen
in the livers from cirrhosis rats. (14C) Minimal collagen deposition in the liver of the hepatoprotective rat treated with Silymarin. (14D) Moderated
collagen deposition and moderate congestion around the central vein in the livers of rats treated with low dose CLRE. (14E) Mild collagen
deposition was observed in the livers of rats treated with high dose CLRE. (Original magnification ×20).
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suggested to be one mechanism of TAA-induced hep-
atotoxicity [44]. Our results revealed that administration
of CLRE to the cirrhotic rats significantly alleviated the
TAA-suppressive effect on antioxidant enzymes SOD
and CAT by maintaining the activity of these enzymes at
higher levels (Figures 7 and 8). Optimizing the level of
hepatocellular antioxidant enzymes led to removal of oxi-
dative stress by scavenging the free radicals resulting from
TAA-toxicity. Antioxidant activity of CLRE may be attrib-
uted to the antioxidant properties of phenol compound
constituents which constitute 3-15% of rhizomes [45] and
that TPC is equivalent to gallic acid (517.54 ± 0.049 mg
GAE/mg extract). Toxins target metabolically active hepa-
tocytes [46] leading to hepatocyte dysfunction and therelease of ROS, and fibrogenic and inflammatory media-
tors. Several studies have suggested that part of
hepatocellular injury induced by TAA is mediated through
oxidative stress caused by the action of cytokines through
lipid peroxidation [47]. The free radicals resulting
from TAA metabolism may activated myofibroblasts,
that secrete fibrinogen and growth factors [48]. TGF-β1,
a prominent profibrogenic cytokine with antiproliferative
effects that can up-regulate the deposition of ECM [49],
was present at high levels in the cirrhosis rats of Group 2
compared with the other groups (Figure 9). In
addition, the pro-inflammatory cytokine TNF-α [50] was
elevated in the cirrhosis rats indicating a high inflamma-
tory state in the cirrhotic liver. Low or high dose CLRE ad-










Figure 15 Bax and Bcl2 staining of representative livers sampled from rats in different experimental groups. (A-I) Less apoptosis
indicated by few Bax-positive hepatocytes (white arrow) and (B-I) more Bcl2-positive hepatocytes (black arrow) in liver tissues from cirrhosis rats.
(A-II) High numbers of Bax-positive hepatocytes (White arrow) and (B-II) very less Bcl2-positive hepatocytes (black arrow) in the livers from
hepatoprotected rats treated with Silymarin. (A-III) Moderate apoptosis as indicated by moderate Bax staining (white arrow) and (B-III) moderate
Bcl2 staining (black arrow) indicating moderate apoptosis in the livers from rats treated with low dose CLRE. (A-V) High numbers of Bax-positive
cells (white arrow) with severe apoptosis and (B-V) very less Bcl2-positive hepatocytes (black arrow) were observed in the liver of rats treated with
high dose CLRE. (Original magnification ×40).





Figure 16 PCNA staining of livers sampled from rats in different experimental groups. (16A) Normal livers without signs of PCNA
expression in hepatocytes from control rats. (16B) Severe fibrosis with greater PCNA expression in the hepatocytes from cirrhosis rats. (16C) Less
PCNA-stained hepatocytes (arrow) indicating less hepatocyte regeneration in the liver of hepatoprotected rats treated with Silymarin. (16D)
Moderate hepatocyte regeneration as indicated by moderate PCNA staining (arrow) in the liver of rats treated with low dose CLRE. (16E) Minor
PCNA expression (arrow) with few regenerative hepatocytes was observed in the liver of rats treated with high dose CLRE. (Original
magnification ×40).
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inhibitory effects of curcumin on the transcription of nu-
clear factor NF-κB binding activity, and TNF-α [30] and
TGF-β1 expression [51].
Upon liver injury, hepatic stellate cells acquire a highly
proliferative index producing fibrillar collagen within the
injured liver [52]. Our biochemical findings were supported
by the gross and histopathological examinations of the rat
liver tissues (Figures 10 and 11) showing that livers from
CLRE-treated rats had nearly normal liver architecture. In
addition, Masson’s Trichrome staining showed significant
improvement in collagen synthesis upon administration ofCLRE to the rats treated with TAA. This was probably due
to the inhibitory effect of CLRE on hepatic stellate cell acti-
vation. These findings confirmed previous studies, demon-
strating the attenuating effect of curcumin against liver
fibrosis by inhibiting HSC activity [53]. Curcumin, the
most common antioxidant constituent of Curcuma longa
rhizome extract, was reported to enhance apoptosis of
damaged hepatocytes which might be the protective mech-
anism whereby curcumin down-regulated inflammatory
effects and fibrogenesis of the liver [53].
A number of studies have focused on the molecular
regulation of apoptosis. Over expression of the pro-
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chronic hepatitis [54]. Toxicity induced by TAA was found
to be accompanied by elevation in Bax protein levels and
reduction in the anti-apoptotic protein Bcl2 and its trans-
location into the mitochondria, causing apoptosis [55]. In
the current study, we observed significant increase in the
serum level of Bax protein and decrease in Bcl-2 protein
in silymarin-treated and CLRE- treated animals compared
with the cirrhosis group animals. This was confirmed by
the ratio Bax/Bcl-2 which was high in the treated groups
compared with the cirrhosis group and the large number
of Bax positive-stained hepatocytes together with few Bcl2
positive-stained hepatocytes both doses of CLRE-treated
animals, and in Silymarin-treated animals compared with
the cirrhosis Group (Figures 10, 11, 13A and 13B) indicat-
ing the susceptibility of these cells to apoptosis and the
role of curcuminoids in inducing apoptosis [53]. Further-
more, those animals on daily feeding with CLRE along
with TAA injections thrice weekly for 8 weeks attenuated
hepatocyte proliferation and regeneration as indicated by
a significant decrease in PCNA positive-stained cells in
the liver sections from the low dose and high dose-treated
groups similar to that in the Silymarin-treated group
(Figure 14) [56]. These results were consistent with previ-
ous reports that curcumin the active ingredient of CLRE
extract had inhibitory effect on hepatocyte proliferation
[53]. Treating the animals with CLRE extract inhibited the
necrotic effect due to thioacetamide administration by
modifying necrosis into apoptosis, which might be through
cytochrome release from mitochondria and caspase activa-
tion [57]. This modification in vivo would scale down the
release of inflammatory mediators that would prevent pro-
gressive live damage. The ethanolic extract of C. longa
rhizomes showed a significant hepatoprotective effect when
orally administrated in doses of 250 mg/kg and 500 mg/kg,
and the protective effect was dose-dependent. The main
constituents of CLRE extract are the flavonoid curcumin
and various volatile oils, including tumerone, atlantone, and
zingiberene. The hepatoprotective effects of turmeric and
curcumin might be due to direct antioxidant and free-
radical scavenging mechanisms, as well as the ability to
indirectly augment glutathione levels, thereby aiding in
hepatic detoxification [58]. The volatile oils and curcumin
of C. longa exhibit potent anti-inflammatory effects [59].
Conclusion
In conclusion, our results demonstrated that the progres-
sion of TAA-induced liver cirrhosis could be prevented or
reduced using the ethanol extract of C. longa rhizomes.
The plant natural extract exerted its hepatoprotective ef-
fect by preventing the harmful cascade of events induced
by TAA toxicity. This hepatoprotective capability of CLRE
preserved the liver’s status quo in terms of its properties,
functions and structure against toxins, and warrantedfurther study to explore its pharmacologic potential in
treating liver cirrhosis. In addition, Curcumin might be
predominantly responsible for the hepatoprotective effect
of CLRE rhizome extract. These findings would encourage
further studies on the pharmacological significance of
using plant extracts as alternative medicines for treating
liver cirrhosis.
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